- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05153564
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
November 10, 2023 updated by: Novo Nordisk A/S
Investigation of the Effect of Subcutaneously Co-administered Semaglutide and NNC0480-0389 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Healthy Postmenopausal Females
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
It is expected that the combination will further improve the blood sugar control compared to semaglutide therapy alone.
The study will investigate the influence of the combination of semaglutide and NNC0480-0389 on the blood levels of a birth control pill (a combined oral contraceptive consisting of ethinylestradiol and levonorgestrel) and paracetamol.
Participants will get semaglutide and NNC0480-0389 as injection under the skin of their belly using a pen-injector.
The injections will be given once weekly for 14 weeks.
Additionally, participants will at two occasions get paracetamol as soluble tablet in connection with a standardised breakfast meal.
Further, participants will get the birth control pill in form of tablets in two periods of 8 days each.
Participants will get the combination of semaglutide and NNC0480-0389 as well as paracetamol and the combined contraceptive in any case.
The study participation will last up to about 24 weeks.
Participants will have 25 visits at the study centre.
For 4 of the visits participants will stay at the study centre; the remaining visits will be outpatient.
Only healthy postmenopausal women can take part in this study.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Postmenopausal female, aged greater than or equal to 45 years at the time of signing informed consent
- Body mass index between 20.0 and 29.9 kilogram per meter square (kg/m^2) (both inclusive)
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
Exclusion Criteria:
- Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- HbA1c greater than or equal to 6.5 % (48 millimoles per mole (mmol/mol)) at screening
- Use of prescription medicinal products or non-prescription drugs including any herbal medicine known to interfere with the metabolic cytochrome P450 enzyme (CYP) pathways, such as hypericum (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days before screening. Exceptions are routine vitamins, occasional use of paracetamol, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation
- Use of hormone replacement therapy within 4 weeks before first dose of trial product or intention to initiate treatment with hormone replacement therapy during the study
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: One-sequence cross-over arm
|
Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum.
once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c.
(under the skin) injections for 14 weeks.
NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c.
(under the skin) injections for 14 weeks.
Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration.
One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the ethinylestradiol plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,EE,SS)
Time Frame: From pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Measured in h*pg/mL
|
From pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Area under the levonorgestrel plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,LN,SS)
Time Frame: From pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Measured in h*pg/mL
|
From pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum concentration of ethinylestradiol at steady state (Cmax,EE,SS)
Time Frame: Within pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Measured in pg/mL
|
Within pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Maximum concentration of levonorgestrel at steady state (Cmax,LN,SS)
Time Frame: Within pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Measured in pg/mL
|
Within pre-dose to 24 hours after last dosing of oral contraceptive on day 8 and day 100
|
Area under the paracetamol concentration-time curve for 0-60 minutes following a standardised meal (AUC0-60min,para)
Time Frame: From pre-dose to 60 minutes after dosing of paracetamol on day 1 and day 93
|
Measured in h*μg/mL
|
From pre-dose to 60 minutes after dosing of paracetamol on day 1 and day 93
|
Area under the paracetamol concentration-time curve for 0-300 minutes following a standardised meal (AUC0-300min,para)
Time Frame: From pre-dose to 300 minutes after dosing of paracetamol on day 1 and day 93
|
Measured in h*μg/mL
|
From pre-dose to 300 minutes after dosing of paracetamol on day 1 and day 93
|
Maximum observed paracetamol concentration following a standardised meal (Cmax,para)
Time Frame: Within pre-dose to 300 minutes after dosing of paracetamol on day 1 and day 93
|
Measured in μg/mL
|
Within pre-dose to 300 minutes after dosing of paracetamol on day 1 and day 93
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency dept. 1452, Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 13, 2021
Primary Completion (Actual)
August 13, 2022
Study Completion (Actual)
September 1, 2022
Study Registration Dates
First Submitted
December 8, 2021
First Submitted That Met QC Criteria
December 8, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Estimated)
November 13, 2023
Last Update Submitted That Met QC Criteria
November 10, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Contraceptives, Postcoital, Hormonal
- Ethinyl estradiol, levonorgestrel drug combination
- Ethinyl Estradiol-Norgestrel Combination
Other Study ID Numbers
- NN9389-4681
- 2021-003060-27 (EudraCT Number)
- U1111-1266-3910 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Semaglutide 1.34 mg/mL
-
Novo Nordisk A/SCompletedHealthy Volunteers (Diabetes Mellitus, Type 2)United Kingdom
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Healthy ParticipantsUnited States
-
Novo Nordisk A/SCompleted
-
Kirsi PietiläinenTurku University Hospital; University of HelsinkiRecruitingType2 DiabetesFinland
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Jan FrystykRegion of Southern Denmark; Region Zealand; Steno Diabetes Center Sjaelland; Steno...RecruitingSchizophrenia | Prediabetic StateDenmark
-
Merck Sharp & Dohme LLCCompletedNonalcoholic Fatty Liver Disease | Nonalcoholic SteatohepatitisUnited States, Argentina, Australia, Canada, France, Israel, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine
-
Peking University First HospitalRecruitingSemaglutide | PCOS (Polycystic Ovary Syndrome)China
-
Filip Krag KnopRecruitingObesity | Type 2 DiabetesDenmark
-
Geisinger ClinicTerminatedObesity | Diabetic Kidney Disease | Type 2 Diabetes Mellitus in Obese | CKD | Severe ObesityUnited States